PharmAbcine collaborates with MSD for Phase 2 study of olinvacimab

South Korea’s clinical-stage biotech firm, PharmAbcine Inc., has reportedly announced establishing a clinical partnership with MSD to initiate the Phase 2 combination trial of olinvacimab and KEYTRUDA in metastatic Triple-Negative Breast Cancer (mTNBC).

Reports suggest that the Phase 2 clinical trial would enroll immune-oncology drug naïve mTNBC patients irrespective of their PD-L1 expression level to study the clinical efficiency, safety, expression level, and pharmacodynamics of VEGFR-2 and PD-L1 after dosing 200mg of pembrolizumab and 16mg per kg of olinvacimab.

As per official sources, both the firms have entered the strategic partnership based on the promising clinical information procured from the Phase 1b olinvacimab and pembrolizumab analysis in mTNBC which is currently ongoing the states of Australia.

Moreover, as per the interim result as of September 2020, the combination therapy demonstrated a manageable safety profile with 50% ORR and 67% DCR in patients who received olinvacimab plus pembrolizumab at the suggested phase 2 dose.

Additionally, 1 patient in PR presented Complete Response in the target lesion while the other PR patients displayed CR in a non-target lesion.

It has been claimed that under the terms of the agreement, PharmAbcine is likely to sponsor a Phase 2 clinical trial which would apparently take place in both South Korea and Australia, and MSD would potentially supply KEYTRUDA.

Commenting on the collaboration pact, CEO of PharmAbcine, Dr. Jin-San Yoo stated that helping cancer patients has been a core to the company’s mission ever since its inception.

Jin-San Yoo added that based on the safety profile and early clinical efficiency observed in Phase 1b trial, the firm believes that it has a responsibility of exploring olinvacimab in combination with pembrolizumab in mTNBC patients in Phase 2 study.

It was also mentioned that the PharmAbcine team is trying its best so that the multinational clinical study is expected to commence in the first half of 2021.

Source Credit: